CA3024555A1 - T-cell receptors which recognise frameshift mutants of tgf.beta.rii - Google Patents

T-cell receptors which recognise frameshift mutants of tgf.beta.rii Download PDF

Info

Publication number
CA3024555A1
CA3024555A1 CA3024555A CA3024555A CA3024555A1 CA 3024555 A1 CA3024555 A1 CA 3024555A1 CA 3024555 A CA3024555 A CA 3024555A CA 3024555 A CA3024555 A CA 3024555A CA 3024555 A1 CA3024555 A1 CA 3024555A1
Authority
CA
Canada
Prior art keywords
seq
tcr
sequence
amino acid
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3024555A
Other languages
English (en)
French (fr)
Inventor
Else Marit INDERBERG
Gustav Gaudernack
Sebastien Walchli
Gunnar Kvalheim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oslo University Hospital
Original Assignee
Oslo University Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oslo University Hospital filed Critical Oslo University Hospital
Publication of CA3024555A1 publication Critical patent/CA3024555A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
CA3024555A 2016-05-09 2017-05-09 T-cell receptors which recognise frameshift mutants of tgf.beta.rii Pending CA3024555A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1608052.5A GB201608052D0 (en) 2016-05-09 2016-05-09 T-cell receptors which recognise frameshift mutants of TGF-beta RII
GB1608052.5 2016-05-09
PCT/EP2017/061087 WO2017194555A1 (en) 2016-05-09 2017-05-09 T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRII

Publications (1)

Publication Number Publication Date
CA3024555A1 true CA3024555A1 (en) 2017-11-16

Family

ID=56297359

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3024555A Pending CA3024555A1 (en) 2016-05-09 2017-05-09 T-cell receptors which recognise frameshift mutants of tgf.beta.rii

Country Status (13)

Country Link
US (1) US20190336529A1 (enExample)
EP (1) EP3455249B1 (enExample)
JP (1) JP2019517790A (enExample)
KR (1) KR20190016507A (enExample)
CN (1) CN109328196B (enExample)
AU (1) AU2017261684A1 (enExample)
CA (1) CA3024555A1 (enExample)
EA (1) EA201892217A1 (enExample)
GB (1) GB201608052D0 (enExample)
IL (1) IL262873A (enExample)
MX (1) MX2018013581A (enExample)
SG (1) SG11201809716VA (enExample)
WO (1) WO2017194555A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10724043B2 (en) 2016-10-06 2020-07-28 Nantbio, Inc. Multi-pulse transfection methods and cells
WO2018104473A1 (en) 2016-12-07 2018-06-14 Oslo Universitetssykehus Hf Compositions and methods for cell therapy
GB201713078D0 (en) * 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
EP3854802A4 (en) * 2018-09-21 2022-10-12 XLifeSc, Ltd. HIGH AFFINE T-CELL RECEPTOR FOR RECOGNIZING AN AFP ANTIGEN
WO2020201527A1 (en) * 2019-04-04 2020-10-08 Umc Utrecht Holding B.V. Modified immune receptor constructs
GB201907663D0 (en) 2019-05-30 2019-07-17 Ab Mavatar Method for diagnosing colorectal cancer
AU2021351710A1 (en) * 2020-10-02 2023-06-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
CA3221568A1 (en) * 2021-05-26 2022-12-01 Board Of Regents, The University Of Texas System Chimeric antigen receptor to target hla-g-positive cancers
WO2023050063A1 (zh) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
WO2024050399A1 (en) 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
AU2024312524A1 (en) * 2023-06-20 2026-01-22 Immunova Therapeutics Llc Synthetic t cell receptors for enhancing memory (stem) t cells using new transmembranes and signaling domains
WO2024260454A1 (zh) * 2023-06-21 2024-12-26 北京可瑞生物科技有限公司 经修饰的tcr恒定区及其在tcr融合蛋白中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
FR2779432A1 (fr) * 1998-06-08 1999-12-10 Transgene Sa Sequence nucleique du recepteur rii du tgfb, peptide code, et utilisations
MX2012001278A (es) * 2009-07-29 2012-03-16 Glaxo Group Ltd Anticuerpos de dominio simple anti-receptor tgf-beta tipo ii.
EP2714735B1 (en) * 2011-06-03 2021-07-21 XOMA Technology Ltd. Antibodies specific for tgf-beta
JP6548579B2 (ja) * 2012-12-06 2019-07-24 ヴィクトリア リンク リミテッド コンジュゲート化合物
WO2015169853A1 (en) * 2014-05-06 2015-11-12 Universitetet I Oslo Engineered invariant chain molecule for improved mhc class i loading
US20170106066A1 (en) * 2014-06-10 2017-04-20 Universitetet I Oslo Engineered invariant chain molecule for improved mhc class i loading

Also Published As

Publication number Publication date
SG11201809716VA (en) 2018-11-29
EP3455249A1 (en) 2019-03-20
CN109328196B (zh) 2022-11-01
EA201892217A1 (ru) 2019-08-30
JP2019517790A (ja) 2019-06-27
US20190336529A1 (en) 2019-11-07
WO2017194555A1 (en) 2017-11-16
MX2018013581A (es) 2019-07-04
IL262873A (en) 2019-01-31
KR20190016507A (ko) 2019-02-18
AU2017261684A1 (en) 2018-12-13
CN109328196A (zh) 2019-02-12
GB201608052D0 (en) 2016-06-22
EP3455249B1 (en) 2023-05-03

Similar Documents

Publication Publication Date Title
EP3455249B1 (en) T-cell receptors which recognise frameshift mutants of tgfbetarii
US20240059754A1 (en) Chimeric antigen receptors and enhancement of anti-tumor activity
KR102523449B1 (ko) T 세포 수용체
KR102267345B1 (ko) Ｔ 세포 수용체
US20220119477A1 (en) Tcr and peptides
TW201900675A (zh) Ｔｃｒ及肽
KR20230007559A (ko) 태그된 키메라 이펙터 분자 및 그의 리셉터
US20190048061A1 (en) Anti-cd37 chimeric antigen receptors and immune cells expressing them
ES2749903T3 (es) Proteína quimérica
KR20170092535A (ko) T 세포 수용체
WO2016184592A1 (en) T cell receptor with specificity for myeloperoxidase peptide and uses thereof
BR112020001605A2 (pt) métodos para produzir composições de células geneticamente modificadas e composições relacionadas
Matsuzaki et al. A rare population of tumor antigen-specific CD4+ CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells
JP2023525049A (ja) ナチュラルキラー細胞を標的とするキメラ抗原受容体（ｃａｒ）
CN115768464A (zh) 产生工程化记忆样nk细胞及其组合物的方法
JP2025505546A (ja) キメラｉｌｔ受容体組成物及び方法
US12071467B2 (en) Specific binding molecules for hTERT
US20250170175A1 (en) Binding proteins for terminal deoxynucleotidyl transferase (tdt)
CA3250186A1 (en) Specific binding proteins for RAS neo-antigens and their uses
EA042909B1 (ru) Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, КОТОРЫЕ РАСПОЗНАЮТ МУТАНТНЫЕ ВАРИАНТЫ СО СДВИГОМ РАМКИ СЧИТЫВАНИЯ TGFβRII
KR20240099260A (ko) 변형된 결합 단백질 및 이의 치료적 용도

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220429